In the monarcHER trial, abemaciclib plus trastuzumab with or without fulvestrant was compared to chemotherapy plus trastuzumab in patients with HER2-positive breast cancer who have received two or more previous therapies. The gene discussed is ERBB2; the disease is breast carcinoma.